What Fueled The Previous Growth In The Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathy market has seen considerable growth due to a variety of factors.
• The non-proliferative diabetic retinopathy market has grown significantly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025, at a compound annual growth rate (CAGR) of 8.4%.
The growth is driven by the increasing prevalence of diabetes, the aging population, improved awareness, advancements in research, lifestyle changes, and better diabetes management.
How Does the Forecast Look for the Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathy market is expected to maintain its strong growth trajectory in upcoming years.
• The non-proliferative diabetic retinopathy market is anticipated to grow strongly, reaching $3.87 billion by 2029 with a CAGR of 8.0%.
The growth is attributed to telemedicine adoption, novel therapeutics, AI integration, increasing R&D investments, and healthcare infrastructure expansion. Trends include AI adoption for diagnosis, telemedicine and remote monitoring solutions, personalized medicine for diabetic retinopathy, a focus on prevention and early intervention, and the growing importance of patient-centered care models.
What Are The Leading Drivers Of Growth In The Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathy market is poised for substantial growth, propelled by the escalating rates of diabetes. Diabetes, a long-term metabolic disorder, is marked by high blood sugar levels resulting from insufficient insulin production or insulin resistance from the body's cells. Physical inactivity, poor diet, and genetic factors often trigger diabetes. Non-proliferative diabetic retinopathy occurs when diabetes damages retina's blood vessels, primarily due to prolonged exposure to excess glucose in the bloodstream. This condition may lead to impaired vision or even blindness. For example, in June 2024, the National Health Service, a UK government department, reported that the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes in 2023. This moved the total tally of people suffering from non-diabetic hyperglycemia or pre-diabetes registered with a GP to 3,615,330, experiencing a significant increase compared to 3,065,825 in 2022, underlining a rise of nearly 20%. Thus, the surge in diabetes cases is fuelling the expansion of the non-proliferative diabetic retinopathy market.
How Are The Segments Defined Within The Global Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Pre-Book The Non-Proliferative Diabetic Retinopathy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Non-Proliferative Diabetic Retinopathy Market?
Leading firms in the non-proliferative diabetic retinopathy market are harnessing the power of artificial intelligence (AI) in their camera equipment to enhance patient results and push the boundaries of ophthalmic imaging. These AI-powered cameras in ophthalmic imaging consist of devices that are fitted with AI algorithms for image acquisition, analysis, and interpretation for diagnostic and therapeutic purposes. As an example, in May 2024, Finland's medical technology enterprise, Optomed, introduced its product, Optomed Aurora AEYE. This innovative device, a handheld AI fundus camera, is designed for instantaneous detection of more than mild diabetic retinopathy. The groundbreaking device merges the convenience of a portable camera and the potency of AI, providing superior quality retinal images for prompt detection and tracking of an array of eye diseases. The Optomed Aurora AEYE is equipped with AI algorithms assisting healthcare workers in retinal image analysis for fast and precise diagnosis of conditions like diabetic retinopathy, glaucoma, and age-related macular degeneration.
Who Are the Key Players In The Non-Proliferative Diabetic Retinopathy Market?
Major companies operating in the non-proliferative diabetic retinopathy market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• AbbVie Inc.
• Bayer AG
• Abbott Laboratories
• Novartis AG
• Eli Lilly and Company
• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Genentech Inc.
• Carl Zeiss Meditec AG
• ZEISS Group
• Santen Pharmaceutical Co. Ltd.
• Santen Inc.
• Topcon Corporation
• Lumenis Ltd.
• Alimera Science
• Ocular Therapeutix Inc.
• Acucela Inc.
• Ampio Pharmaceuticals
• Kowa Company Ltd.
• Nidek Co. Ltd.
What Is The Most Dominant Region In The Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
